Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including a late-breaker, at the upcoming European Association for the Study of the Liver (EASL) International Liver Congress taking place in Milan, Italy from June 5-8, 2024.
加利福尼亚州南旧金山，2024年5月7日（GLOBE NEWSWIRE）——Pliant Therapeutics, Inc.（纳斯达克股票代码：PLRX）是一家处于后期阶段的生物技术公司，也是治疗纤维化疾病的新疗法的发现和开发的领导者，今天在即将在意大利米兰举行的欧洲肝脏研究协会（EASL）国际肝脏大会上宣布了两张海报演讲，包括一篇最新文章 2024 年 6 月 5 日至 8 日。
Title: Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: Updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC Phase 2a trial
Late Breaker Abstract Number: LB27
Presenter: Michael Trauner, M.D., Chair of Gastroenterology and Hepatology, Department of Medicine III, Medical University Clinic, Vienna, Austria
Presentation Date and Time: Wednesday, June 5, 2024, 8:30 a.m. – Saturday, June 8, 2024, 5:00 p.m. CEST
标题：口服α-v/β-6和α-v/β-1整合素抑制剂bexotegrast治疗原发性硬化性胆管炎：更新后的INTEGRIS-PSC 2a期试验为期12周的中期安全性和有效性分析
Late Breaker 摘要编号：LB27
主持人：迈克尔·特劳纳，医学博士，奥地利维也纳医科大学诊所第三医学系胃肠病学和肝病学主任
演讲日期和时间：2024 年 6 月 5 日星期三上午 8:30 — 2024 年 6 月 8 日星期六，欧洲中部标准时间下午 5:00
Title: Dual alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast targets TGF-beta inhibition to specific cell types in human liver explant tissue with biliary fibrosis
Abstract Number: 1627
Presenter: Johanna Schaub, Ph.D., Principal Scientist II, Translational Sciences, Pliant Therapeutics
Presentation Date and Time: Thursday, June 6, 2024, 8:30 a.m. – 6:00 p.m. CEST
标题：双α-v/β-6和α-v/β-1整合素抑制剂 bexotegrast 靶向胆道纤维化的人类肝脏外植组织中特定细胞类型的 TGF-β 抑制
摘要编号：1627
演讲者：Johanna Schaub，博士，Pliant Therapeutics 转化科学二级首席科学家
演讲日期和时间：欧洲中部标准时间 2024 年 6 月 6 日星期四上午 8:30 至下午 6:00